TOXICOLOGICAL SUBSTANTIATION OF THE MEDICAL AND SANITARY STANDARD FOR THE PERMISSIBLE CONTENT OF ANTRAL® IN THE AIR OF THE WORKING AREA

Abstract

Antral® is a domestic hepatoprotector for the treatment of acute and chronic hepatitis of various genesis, non-alcoholic fatty liver disease, as well as a drug of choice for such nosological conditions as atherosclerosis, blood clotting disorders, diabetes mellitus, coronary heart disease, obstructive nephropathy complicated by infectious and inflammatory processes, etc. in their independent course or against the background of chronic liver disease.In the conditions of chemical and pharmaceutical production, Antral® in the form of an aerosol enters the air of production facilities and can adversely affect workers, which necessitates the development of a health standard for the permissible content in the air of the working area. The aim of the study was to experimentally determine the toxicity parameters of Antral® to assess the nature of its biological effect on the body of warm-blooded animals and to substantiate the maximum permissible concentration in the air of the work area.Antral® was studied in acute, subacute and chronic experiments. The work was carried out on laboratory animals (male white rats, male white mice, guinea pigs and rabbits). Experimental studies have established that Antral® belongs to the 3rd hazard class in terms of acute oral toxicity, to the 2nd hazard class in terms of acute inhalation toxicity, and has no skin-resorptive and local irritant effects when applied to the skin and mucous membranes. In the subchronic toxicity test, the average cumulative activity of Antral® was found. No allergenic effect of Antral® was detected in animal studies. Regardless of the dose, Antral® reduces sperm survival. The maximum permissible concentration of Antral® in the air of the working area is justified at the level of 5,0 mg/m3 aerosol, hazard class 2.